David Scott Miller


AuthID: R-00K-250

Confirmed Publications: 293



201
TITLE: Clinical applications of hormonal therapy in ovarian cancer  Full Text
AUTHORS: Gautam G Rao; David Scott Miller ;
PUBLISHED: 2005, SOURCE: Current Treatment Options in Oncology, VOLUME: 6, ISSUE: 2
INDEXED IN: Scopus CrossRef: 6
IN MY: ORCID
202
TITLE: Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles  Full Text
AUTHORS: Isaac Lavie; Gautam G Rao; Diego H Castrillon; David Scott Miller ; John O Schorge;
PUBLISHED: 2005, SOURCE: American Journal of Obstetrics and Gynecology, VOLUME: 192, ISSUE: 5 SPEC. ISS.
INDEXED IN: Scopus CrossRef: 23
IN MY: ORCID
203
TITLE: Fertility-sparing surgery for ovarian low malignant potential tumors  Full Text
AUTHORS: Gautam G Rao; Elizabeth N Skinner; Paola A Gehrig; Linda R Duska; David Scott Miller ; John O Schorge;
PUBLISHED: 2005, SOURCE: Gynecologic Oncology, VOLUME: 98, ISSUE: 2
INDEXED IN: Scopus CrossRef: 40
IN MY: ORCID
204
TITLE: Fertility-sparing surgery for ovarian low malignant potential tumors
AUTHORS: Gautam G Rao; Elizabeth N Skinner; Paola A Gehrig; Linda R Duska; David Scott Miller ; John W Schorge;
PUBLISHED: 2005, SOURCE: Obstetrical and Gynecological Survey, VOLUME: 60, ISSUE: 12
INDEXED IN: Scopus CrossRef
IN MY: ORCID
205
TITLE: Ovarian preservation in stage I low-grade endometrial stromal sarcomas
AUTHORS: Andrew J Li; Robert L Giuntoli; Richard Drake; Sharon Young Byun; Francisco Rojas; Denise Barbuto; Nancy Klipfel; Pamela Edmonds; David Scott Miller ; Beth Y Karlan;
PUBLISHED: 2005, SOURCE: Obstetrics and Gynecology, VOLUME: 106, ISSUE: 6
INDEXED IN: Scopus CrossRef: 80
IN MY: ORCID
206
TITLE: Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: A Gynecologic Oncology Group study  Full Text
AUTHORS: Agustin A Garcia; John A Blessing; Heinz Josef Lenz; Kathleen M Darcy; Robert S Mannel; David Scott Miller ; Nader Husseinzadeh;
PUBLISHED: 2005, SOURCE: Gynecologic Oncology, VOLUME: 96, ISSUE: 3
INDEXED IN: Scopus CrossRef: 11
IN MY: ORCID
207
TITLE: Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study  Full Text
AUTHORS: David Scott Miller ; John A Blessing; Steven Waggoner; Jeanne Schilder; Joel Sorosky; Jeffrey Bloss; Russell Schilder;
PUBLISHED: 2005, SOURCE: Gynecologic Oncology, VOLUME: 96, ISSUE: 1
INDEXED IN: Scopus CrossRef: 16
IN MY: ORCID
208
TITLE: Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study  Full Text
AUTHORS: David Scott Miller ; John A Blessing; Jeanne Schilder; Adnan Munkarah; Yi Chun Lee;
PUBLISHED: 2005, SOURCE: Gynecologic Oncology, VOLUME: 98, ISSUE: 2
INDEXED IN: Scopus CrossRef: 43
IN MY: ORCID
209
TITLE: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
AUTHORS: Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; Scott S McMeekin; Joel Sorosky; David Scott Miller ; Lynne A Eaton; James V Fiorica; Denise Mackey;
PUBLISHED: 2005, SOURCE: Journal of Clinical Oncology, VOLUME: 23, ISSUE: 21
INDEXED IN: Scopus CrossRef: 418
IN MY: ORCID
210
TITLE: Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis  Full Text
AUTHORS: Jayanthi S Lea; Robert Coleman; Aleena Kurien; John O Schorge; David Scott Miller ; John D Minna; Carolyn Y Muller;
PUBLISHED: 2004, SOURCE: American Journal of Obstetrics and Gynecology, VOLUME: 190, ISSUE: 3
INDEXED IN: Scopus CrossRef: 35
IN MY: ORCID
Page 21 of 30. Total results: 293.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service